Business Insights

Assessing drug target association from biological evidences

July 7, 2022

Assessing drug
The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Spotlight

Dipharma

The Dipharma Group is one of the leading European manufacturers of Bulk Active Pharmaceutical Ingredients having a portfolio of more than 50 products, with Drug Master Files lodged worldwide. Dipharma serves top ranking pharmaceutical companies in Europe, U.S.A. and Japan. Supported by a fully equipped R&D Centre, its core technologies are Nitration, Nitro esterification, Azide Chemistry, High Pressure Hydrogenation, Chiral Synthesis, Organometallic Chemistry and Enzymatic Processes.

OTHER WHITEPAPERS
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More
news image

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Read More
news image

Shifting to an Audience-Focused Product Marketing Strategy

whitePaper | February 24, 2023

The WBR Insights research team surveyed 100 leaders from pharmaceutical companies to generate the results featured in this report. The respondents occupy roles in marketing, sales, commercial strategy, and product development.

Read More
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

Shining a Light on Lipid Nanoparticle Characterization

whitePaper | October 3, 2022

Next-Generation Synthetic Biology Workflow Platform Codex DNA’s BioXp 9600 system is a next-generation high throughput platform intended for automated synthesis of gene fragments and clones from digital sequences.

Read More

Spotlight

Dipharma

The Dipharma Group is one of the leading European manufacturers of Bulk Active Pharmaceutical Ingredients having a portfolio of more than 50 products, with Drug Master Files lodged worldwide. Dipharma serves top ranking pharmaceutical companies in Europe, U.S.A. and Japan. Supported by a fully equipped R&D Centre, its core technologies are Nitration, Nitro esterification, Azide Chemistry, High Pressure Hydrogenation, Chiral Synthesis, Organometallic Chemistry and Enzymatic Processes.

Events